CIC
IBB icon

Concord Investment Counsel’s iShares Biotechnology ETF IBB Stock Holding History

Concord Investment Counsel’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.6M Sell
27,238
-282
-1% -$48.2K 1.55% 23
2025
Q4 		$4.64M Sell
27,520
-1,012
-4% -$164K 1.51% 22
2025
Q3 		$4.12M Buy
+28,532
New +$3.89M 1.31% 22
2024
Q1 		$4.52M Buy
+32,975
New +$4.5M 1.63% 19

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Concord Investment Counsel's IBB Position: Q1 2026 in Review

Concord Investment Counsel reduced its iShares Biotechnology ETF (IBB) stake by 1% in Q1 2026, selling an estimated $48.2K and leaving 27,238 shares worth $4.6M. The position accounts for 1.55% of the portfolio, ranked #23.

Concord Investment Counsel first reported a position in IBB in Q1 2024 and has held it in 4 quarters since. The position peaked at $4.64M in Q4 2025. 919 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

  • Concord Investment Counsel held 27,238 shares of iShares Biotechnology ETF worth $4.6M as of Q1 2026.
  • Concord Investment Counsel sold 282 iShares Biotechnology ETF shares in Q1 2026, an estimated $48.2K.
  • iShares Biotechnology ETF made up 1.55% of Concord Investment Counsel's portfolio in Q1 2026, its #23 holding.
  • Concord Investment Counsel first reported a position in iShares Biotechnology ETF in Q1 2024 and has held it in 4 quarters since.
  • Concord Investment Counsel's iShares Biotechnology ETF position peaked at $4.64M in Q4 2025.
  • 919 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Concord Investment Counsel's 13F filing for Q1 2026, filed 13 May 2026.